The global wound care biologics market is expected to reach USD 2.26 Billion by 2023 from USD 1.42 Billion in 2018, at a CAGR of 9.8%. Market growth is mainly driven by factors such as the increasing incidence of diabetic foot ulcers, increasing geriatric population, and increasing burn injuries globally. On the other hand, the high cost of wound care biologics and the higher rejection rate associated with skin grafts & substitutes will restrain the growth of this market.
Browse 87 market data Tables and 32 Figures spread through 123 Pages and in-depth TOC on "Wound Care Biologics Market"
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=259878425
The biological skin substitutes segment is estimated to account for the largest share of the wound care biologics market in 2018.
On the basis of product, the wound care biologics market is bifurcated into biological skin substitutes and topical agents. In 2018, the biological skin substitutes segment is expected to account for the largest share of the wound care biologics market. The large share of this segment can be attributed to the rising incidence of diabetes and the subsequent growth in the demand for chronic wound care products across the globe.
Ulcers are anticipated to account for the largest share of the wound care biologics market in 2018.
The three major categories of wounds included in this market are ulcers (including pressure, diabetic foot, venous, and other ulcers), surgical & traumatic wounds, and burns. The ulcers segment is expected to dominate the wound care biologics market in 2018. This segment is also expected to grow at the highest CAGR during the forecast period. Market growth is largely driven by the significantly higher prevalence of diabetic foot ulcers and venous leg ulcers as compared to surgical & traumatic wounds and burns.
The hospitals segment is estimated to grow at the highest CAGR during the forecast period.
Based on end user, the wound care biologics market is segmented into hospitals, ambulatory surgical centers, and burn centers & wound clinics. The hospitals segment is expected to grow at the highest CAGR during the forecast period. The high and rising need for wound care services among the rapidly growing geriatric population worldwide is one of the major factors responsible for the growing demand for wound care biologics in hospitals.
North America is expected to command the largest share of the market in 2018.
In this report, the wound care biologics market is segmented into North America, Europe, Asia Pacific (APAC), and the Rest of the World (RoW). In 2018, North America is expected to account for the largest share the global wound care biologics market. The large share of the North American market can primarily be attributed to the high prevalence of venous leg ulcers and diabetic foot ulcers and the strong presence of major market players in this region.
Key players in the wound care biologics market include Smith & Nephew (UK), Mölnlycke Health Care AB (Sweden), Integra LifeSciences Corporation (US), Wright Medical (US), MiMedx Group (US), Vericel Corporation (US), Anika Therapeutics (US), Osiris Therapeutics (US), Organogenesis (US), Kerecis (Iceland), Solsys Medical (US), ACell (US), Lavior Inc. (US), and Marine Polymer Technologies, Inc. (US).
Wound Care Biologics Market
US EVERY YEAR FOR THEIR
HOME ❯ TOP MARKET REPORTS ❯ WOUND CARE BIOLOGICS MARKET
Wound Care Biologics Market by Product (Biological Skin Substitutes
(Biosynthetic Products), Topical Agents), Wound Type (Diabetic Foot
Ulcer, Pressure Ulcers, Surgical & Traumatic Wound), End User
(Hospitals, Burn Centers) - Global Forecast to 2023
[123 Pages Report] The wound care biologics market is expected to reach USD 2.26 Billion by 2023
from USD 1.29 Billion in 2017 at a CAGR of 9.8%. The base year for this study is 2017 and the
forecast period is 2018–2023.
The objectives of this study are as follows:
To define, describe, and forecast the market by product, wound type, end user, and region
To forecast the revenue of the market segments with respect to four main regional segments,
namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW)
To identify micromarkets and the drivers, opportunities, and trends affecting the growth of the
To strategically analyze market segments and subsegments with respect to individual growth
trends, prospects, and contributions to the overall market
To analyze opportunities in the market for stakeholders and provide details of the competitive
landscape for market leaders
To profile key players and comprehensively analyze their market shares and core
competencies in terms of market developments and growth strategies
To track and analyze competitive developments such as collaborations, acquisitions, product
launches, expansions, and R&D activities in the market
Top-down and bottom-up approaches were used to estimate and validate the size of wound care
biologics industry and the size of various other dependent submarkets. The overall market size
was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned
in the market segmentation—by product, wound type, end u